Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis

OncoImmunology

Volumn 1, Issue 3, 2012, Pages 380-382

  Labidi Galy, Sana Intidhar ^a,b,c,d,e   Treilleux, Isabelle ^e   Goddard Leon, Sophie ^e   Combes, Jean Damien ^e   Blay, Jean Yves ^a,b,c,d,e   Ray Coquard, Isabelle ^e   Caux, Christophe ^a,b,c,d   Bendriss Vermare, Nathalie ^a,b,c,d  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^d LabEx DEVweCAN   (France)

^e CENTRE LÉON BÉRARD   (France)

Author keywords

Immune tolerance; Ovarian cancer; Plasmacytoid dendritic cell; Prognosis; Progression free survival

Indexed keywords

ALPHA INTERFERON;

ARTICLE; AUTOIMMUNITY; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CELL INFILTRATION; CYTOKINE PRODUCTION; EPITHELIUM; FLOW CYTOMETRY; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MALIGNANT ASCITES; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; TISSUE MICROARRAY;

EID: 84869174655     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.18801     Document Type: Article

References (10)

1. Vermi W, Soncini M, Melocchi L, Sozzani S, Facchetti F. Plasmacytoid dendritic cells and cancer. J Leukoc Biol 2011, 90:681-90. http://dx.doi.org/10.1189/jlb.0411190
2. Labidi-Galy SI, Sisirak V, Meeus P, Gobert M, Treilleux I, Bajard A, et al. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res 2011, 71:5423-34. http://dx.doi.org/10.1158/0008-5472.CAN-11-0367
3. Sisirak V, Gobert M, Renaudineau S, Menetrier-Caux C, Aspord C, Banchereau J, et al. Breast tumor environment alters human plasmacytoid dendritic cells functions. In The 10th International Symposium on Dendritic Cells (Kobe, Japan) 2008.
4. Jensen TO, Schmidt H, Moller HJ, Donskov F, Hoyer M, Cjoegren P, et al. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer 2011, Epub ahead of press. http://dx.doi.org/10.1002/cncr.26511
5. Hirsch I, Caux C, Hasan U. Driss-Vermare N, Olive D. Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer. Trends Immunol 2010, 31:391-7. http://dx.doi.org/10.1016/j.it.2010.07.004
6. Mohty M, Jourdan E, Mami NB, Vey N, Damaj G, Blaise D, et al. Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. Blood 2004, 103:4666-8. http://dx.doi.org/10.1182/blood-2003-09-3220
7. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006, 6:836-48. http://dx.doi.org/10.1038/nri1961
8. Golding A, Rosen A, Petri M, Akhter E, Andrade F. Interferon-alpha regulates the dynamic balance between human activated regulatory and effector T cells: implications for antiviral and autoimmune responses. Immunology 2010, 131:107-17
9. Berek JS, Markman M, Blessing JA, Kucera PR, Nelson BE, Anderson B, et al. Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study. Gynecol Oncol 1999, 74:48-52. http://dx.doi.org/10.1006/gyno.1999.5455
10. Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010, 363:2511-21. http://dx.doi.org/10.1056/NEJMoa1004095